Covington Reps AstraZeneca In $500M Amplimmune Buy

Law360, New York (August 26, 2013, 12:27 PM EDT) -- AstraZeneca PLC said on Monday it plans to buy privately held Amplimmune for $500 million, adding the Maryland company's early stage immunotherapy drugs aimed at boosting the British pharmaceutical giant's position in a growing field of cancer treatment.

MedImmune, AstraZeneca's biologics research and development unit, will pay an initial $225 million for all of Amplimmune's shares and plans to fork over an additional $275 million after certain unspecified milestones are met, the company said on Monday. Much of Amplimmune's appeal springs from its focus on a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.